CD8型
肿瘤坏死因子α
细胞毒性T细胞
癌症研究
细胞因子
生物
免疫学
MHC I级
T细胞
过继性细胞移植
黑色素瘤
肿瘤微环境
免疫系统
体外
生物化学
作者
Florie Bertrand,Julia Rochotte,Céline Colacios,Anne Montfort,Anne‐Françoise Tilkin‐Mariamé,Christian Touriol,Philippe Rochaix,Isabelle Lajoie‐Mazenc,Nathalie Andrieu‐Abadie,Thierry Levade,Hervé Benoist,Bruno Ségui
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2015-05-14
卷期号:75 (13): 2619-2628
被引量:108
标识
DOI:10.1158/0008-5472.can-14-2524
摘要
TNF plays a dual, still enigmatic role in melanoma, either acting as a cytotoxic cytokine or favoring a tumorigenic inflammatory microenvironment. Herein, the tumor growth of melanoma cell lines expressing major histocompatibility complex class I molecules at high levels (MHC-I(high)) was dramatically impaired in TNF-deficient mice, and this was associated with enhanced tumor-infiltrating CD8(+) T lymphocytes. Immunodepletion of CD8 T cells fully restored melanoma growth in TNF(-/-) mice. Systemic administration of Etanercept inhibited MHC-I(high) melanoma growth in immunocompetent but not in immunodeficient (IFNγ(-/-), nude, or CD8(-/-)) mice. MHC-I(high) melanoma growth was also reduced in mice lacking TNF-R1, but not TNF-R2. TNF(-/-) and TNF-R1(-/-) mice as well as Etanercept-treated WT mice displayed enhanced intratumor content of high endothelial venules surrounded by high CD8(+) T-cell density. Adoptive transfer of activated TNF-R1-deficient or -proficient CD8(+) T cells in CD8-deficient mice bearing B16K1 tumors demonstrated that TNF-R1 deficiency facilitates the accumulation of live CD8(+) T cells into the tumors. Moreover, in vitro experiments indicated that TNF triggered activated CD8(+) T cell death in a TNF-R1-dependent manner, likely limiting the accumulation of tumor-infiltrating CD8(+) T cells in TNF/TNF-R1-proficient animals. Collectively, our observations indicate that TNF-R1-dependent TNF signaling impairs tumor-infiltrating CD8(+) T-cell accumulation and may serve as a putative target to favor CD8(+) T-cell-dependent immune response in melanoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI